Explore more publications!
Tajikistan Tech Daily
Got News to Share?

Tajikistan Tech Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tajikistan Tech Daily.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on November 10, 2025

HeartCore Granted 180-Day Extension to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
November 10, 2025

HeartCore Granted 180-Day Extension to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

Indeterminate GlobeNewswire
Vittoria Biotherapeutics Announces Presentation of First-in-Human Interim Phase1 Data for VIPER-101 at ASH2025
November 10, 2025

Vittoria Biotherapeutics Announces Presentation of First-in-Human Interim Phase1 Data for VIPER-101 at ASH2025

Indeterminate GlobeNewswire
Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors
November 10, 2025

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

Indeterminate GlobeNewswire
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
November 10, 2025

Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs

Indeterminate GlobeNewswire
Roper Technologies strengthens AI leadership with key executive appointments
November 10, 2025

Roper Technologies strengthens AI leadership with key executive appointments

Indeterminate GlobeNewswire
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025
November 10, 2025

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Indeterminate GlobeNewswire
NewGen Announces Up to US$2 Million Share Repurchase Program
November 10, 2025

NewGen Announces Up to US$2 Million Share Repurchase Program

Indeterminate GlobeNewswire
BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
November 10, 2025

BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial

Indeterminate GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
November 10, 2025

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Indeterminate GlobeNewswire
Genius Group and Nuanu Complete Agreements, With a Combined Valuation of $14 Million, to Launch Genius School and Genius City, Bali
November 10, 2025

Genius Group and Nuanu Complete Agreements, With a Combined Valuation of $14 Million, to Launch Genius School and Genius City, Bali

Indeterminate GlobeNewswire
Arch Biopartners Arranges Non-Brokered Private Placement
November 10, 2025

Arch Biopartners Arranges Non-Brokered Private Placement

Indeterminate GlobeNewswire
Foresight Expands Global Reach Through Strategic Collaboration with Leading Chinese Stereo Solutions Manufacturer
November 10, 2025

Foresight Expands Global Reach Through Strategic Collaboration with Leading Chinese Stereo Solutions Manufacturer

Indeterminate GlobeNewswire
Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
November 10, 2025

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Indeterminate GlobeNewswire
USX Cyber® Launches Guardient® for SMBs as CMMC Enforcement Begins - Helping Businesses Get Compliant Faster, More Affordably, and More Effectively
November 10, 2025

USX Cyber® Launches Guardient® for SMBs as CMMC Enforcement Begins - Helping Businesses Get Compliant Faster, More Affordably, and More Effectively

Indeterminate GlobeNewswire
Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference
November 10, 2025

Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference

Indeterminate GlobeNewswire
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
November 10, 2025

HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health

Indeterminate GlobeNewswire
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
November 10, 2025

Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)

Indeterminate GlobeNewswire
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
November 10, 2025

Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia

Indeterminate GlobeNewswire
Voyager Reports Third Quarter 2025 Financial and Operating Results
November 10, 2025

Voyager Reports Third Quarter 2025 Financial and Operating Results

Indeterminate GlobeNewswire
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
November 10, 2025

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions